338P A new clinically applicable immune-metabolic signature (IMMETCOLS) reveals metabolic singularities in consensus molecular subtypes (CMS) in colorectal cancer

In the last years, a great effort has been made to unify different independent colorectal cancer (CRC) molecular classification systems into four consensus subtypes (CMS). The are found be associated with distinct microenvironmental features and clinical outcome, although metabolic singularities not well established. Metabolic dysregulation reported as hallmark of CMS3 but heterogeneity among other investigated. Here, taking account increasing evidence on importance, for determining response therapies, crosstalk between cells, tumor microenvironment immune we investigated in CMS using genetic immune-metabolic signature (IMMETCOLS).